Vol. 2 No. 5 (2026), Articles
Vol. 2 No. 5 (2026)

BIOTEXNOLOGIK PREPARATLARNING NOJO‘YA TA’SIRLARI VA ULARNI BAHOLASH USULLARI

Articles
Published 2026-01-23
Iskandarova Joziba Bektosh qizi.
Samarqand davlat tibbiyot universiteti, Biotexnologiya, injinering va farmatsiya fakultetining 1-bosqich talabalari
Latifova Fazilat Faxriddin qizi.
Samarqand davlat tibbiyot universiteti, Biotexnologiya, injinering va farmatsiya fakultetining 1-bosqich talabalari
Abduazizova Lola Mexroj qizi.
Samarqand davlat tibbiyot universiteti, Biotexnologiya, injinering va farmatsiya fakultetining 1-bosqich talabalari
PDF

Keywords

biotexnologik preparatlar, nojo‘ya ta’sirlar, toksikologik baholash, farmakovigilans, immunologik testlar, xavfsizlik profili, klinik kuzatuv, in vitro modellar, in vivo modellar, regulyator standartlar.

Abstract

Biotexnologik preparatlar – genetik modifikatsiyalangan yoki biotexnologik usullar bilan ishlab chiqarilgan biologik faol moddalar bo‘lib, ular tibbiyot, farmatsevtika va diagnostika sohalarida keng qo‘llaniladi. Shu bilan birga, ularning qo‘llanilishi ayrim hollarda nojo‘ya ta’sirlarning rivojlanishiga olib kelishi mumkin, bu esa bemor xavfsizligi va davolash samaradorligini ta’minlashda muhim omil hisoblanadi. Nojo‘ya ta’sirlar preparatning tabiati, dozasi, qo‘llanish yo‘li, bemorning individual biologik xususiyatlari va immunologik holatiga bog‘liq bo‘lishi mumkin. Ular klinik jihatdan allergik reaksiyalar, toksik ta’sirlar, autoimmun javoblar, shuningdek, surunkali va kechikkan salbiy effektlar ko‘rinishida namoyon bo‘lishi mumkin. Maqolada biotexnologik preparatlarning potentsial nojo‘ya ta’sirlarini baholash usullari, ularning xavfsizlik profilini aniqlashga qaratilgan zamonaviy metodlar, shu jumladan in vitro va in vivo modellar, immunologik testlar, toksikologik tahlillar va klinik kuzatuvlar yoritiladi. Shuningdek, xavfsizlikni baholashning xalqaro standartlari va reglamentlari, farmakovigilans tizimlarining roli, nojo‘ya ta’sirlarni oldini olish va monitoring qilish strategiyalari batafsil tahlil qilinadi. Mazkur yondashuvlar biotexnologik preparatlar samaradorligini oshirish, xavfsizligini ta’minlash va sog‘liqni saqlash sohasida innovatsion rivojlanishni rag‘batlantirish imkonini beradi.                

PDF

References

1. Biotexnologik preparatlar va ularning klinik xavfsizligi. Toshkent: Tibbiyot nashriyoti, 2020, 1–152.

2. Farmakovigilans: nazariy va amaliy asoslar. Toshkent: Sharq, 2019, 45–98.

3. Clinical safety assessment of biotechnological products. New york: springer, 2018, pp. 12–65.

4. Immunogenicity of biopharmaceuticals: Evaluation and Management. London: Elsevier, 2020, pp. 33–102.

5. Biotexnologik mahsulotlarda toksikologik tadqiqotlar. Toshkent: Fan, 2021, 23–77.

6. In Vitro and In Vivo Models in Biopharmaceutical Safety Testing. Cambridge: Cambridge University Press, 2019, pp. 45–111.

7. Clinical Trials for Biopharmaceuticals: Design and Safety. Boston: Academic Press, 2021, pp. 78–145.

8. Biologics Safety and Monitoring. Berlin: De Gruyter, 2020, pp. 101–168.

9. Biopharmaceuticals: Immunogenicity, Safety, and Clinical Practice. New York: Wiley, 2019, pp. 55–122.

10. Biotexnologik Preparatlarning Innovatsion Rivojlanishi. Tashkent: Tibbiyot Akademiyasi nashriyoti, 2022, 15–82.

11. Pharmacovigilance and Risk Management of Biopharmaceuticals. London: Elsevier, 2018, pp. 22–95.

12. Biologics in Clinical Practice: Safety, Efficacy, and Monitoring. Oxford: Oxford University Press, 2020, pp. 41–107.

13. Xalqaro Standartlar va Reglamentlar: ICH, EMA va FDA Qo‘llanmalari. Tashkent: Sharq, 2021, 12–68.

14. Toxicological Assessment of Recombinant Proteins. New York: Springer, 2019, pp. 30–88.

15. Biopharmaceuticals and Patient Safety. Cambridge: Cambridge University Press, 2021, pp. 77–145.

16. Immunogenicity Assessment of Monoclonal Antibodies. Berlin: De Gruyter, 2020, pp. 55–120.

17. Biotexnologik preparatlar va klinik monitoring. Toshkent: Fan, 2022, 18–93.